MBNL1 and myotonic dystrophy type 1: Pan-HDACi were also exploited for the treatment of Myotonic dystrophy Type 1 (DM1), a genetic rare disease characterized by the expansion of CTG trinucleotide repeats in the 3′ untranslated region of the DMPK gene, that leads to the nuclear sequestration of the alternative splicing factor Muscleblind-like protein 1 (MBNL1).